Compugen Cuts Q1 Loss on Lower Spending | GenomeWeb

NEW YORK (GenomeWeb News) – Compugen today reported that its first quarter net loss declined 8 percent as the firm cuts its R&D and SG&A spending.

The Tel Aviv, Israel-based firm reported no revenues for the three-month period ended March 31, compared with revenues of $281,000 for the first quarter of 2008.

Its net loss decreased to $2.3 million, or $.08 per share, from $2.5 million, or $.09 per share, year over year.

The firm's R&D costs declined 30 percent to $1.4 million from $2 million, and its SG&A spending fell from $1 million to $851,000.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: convergent evolution in bird hemoglobin, and more.

The Wall Street Journal speaks with patients affected by questionable test results from Theranos.

Researchers link variants in TACR3 to hot flashes during menopause, Live Science reports.

Kuwait says it will alter its law requiring citizens and visitors to provide DNA samples, New Scientist reports.